Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion evidence source_evidence_literature NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion SIO_000772 21775097 NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion wasDerivedFrom befree-20150227 NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion wasGeneratedBy ECO_0000203 NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- befree-20150227 importedOn "2015-02-27" NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.